Cell populations derived from adult tissue and stem cells possess a great expectation for the treatment of several diseases. Great efforts have been made to generate cells with therapeutic impact from stem cells. However, it is clear that the development of systems to deliver such cells to induce efficient engraftment, growth, and function is a real necessity. Biologic and artificial scaffolds have received significant attention for their potential therapeutic application when use to form tissues in vitro and facilitate engraftment in vivo. Ultimately more sophisticated methods for decellularization of organs have been successfully used in tissue engineering and regenerative medicine applications. These decellularized tissues and organs appear to provide bioactive molecules and bioinductive properties to induce homing, differentiation, and proliferation of cells. The combination of decellularized organs and stem cells may dramatically improve the survival, engraftment, and fate control of transplanted stem cells and their ultimate clinical utility, opening the doors to a new era of organ engineering.
INTRODUCTION
prolong the survival of animals with liver failure (7, 10, 17, 49, 62) . Liver cell transplantation presents distinct advantages Since the development of techniques for the isolation of individual cells, cell therapies promise to provide over orthotopic liver transplantation (OLT) for organ replacement therapy: cell transplantation is technically cures to multiple diseases and disorders, normally via tissue repopulation, which is the focus of this review. simpler than OLT, requiring only injection/infusion of a cell suspension (31) ; liver cells can be cryopreserved for Potential cell therapies have been most classically introduced to the body via an injection of cells, suspended in future use (22) ; and cells obtained from one donor can be used for multiple patients (33) . Yet, major obstacles an appropriate medium, either into the systemic circulation or directly into the tissue of interest.
to the broad clinical use of cell transplantation include the competition with OLT for the few suitable donor Transplantation of isolated hepatocytes has been considered a potential therapy for the treatment of liver dis-livers, long-term cell engraftment and function, effective and adequate immunosuppressant protocols, and the fact orders. Over the last several decades, laboratories have progressively shown that primary hepatocytes can en-that primary hepatocytes cannot be readily expanded in vitro (1, 7, 49) . These studies have confirmed the ability graft in the liver, spleen, peritoneal cavity, and other extra hepatic sites, and can function following transplan-of transplanted liver cells to participate in the repopulation of damaged or diseased livers and demonstrated tation to correct liver-based errors of metabolism and 656 SOTO-GUITERREZ ET AL. proof of principle for this new therapeutic approach. The CELL TRANSPLANTATION results of many studies, however, are also making clear that at least some of the transplanted cell populations Two general approaches have been taken for cell therapies. The first has been rapid cell isolation and re-regulate liver regeneration in certain advantageous circumstances via the loss of reproductive integrity in en-application of the cells with minimal manipulations (10, 49) . The second, more common, approach has been dogenous hepatocytes, giving preferential proliferation of transplanted hepatocytes.
cell isolation, transport to the lab, and extensive in vitro manipulation before reimplantation (17, 18) . Advantages A wide variety of cell populations have been transplanted in this manner, including different populations of the former approach include minimal cost and minimal oversight by regulatory agencies, whereas the latter of fetal liver cells such as Dlk-1 + cells or Thy-1 − cells (42, 43) purified from unfractionated embryonic day approach is costly and requires manipulation of the cells under current Good Manufacturing Protocols (cGMP) in (ED) 14 fetal liver stem/progenitor cells (43) , xenogeneic hepatocytes (35) , embryonic stem cell-derived he-clean rooms with extensive documentation and close regulatory supervision (9) . patocytes, and even conditionally immortalized cell lines (24). However, studies have uniformly demonstrated large-Liver cell transplantation (LCT) involves the transfer of normal hepatocytes into diseased liver, by injecting scale death of the transplanted cells, extremely poor engraftment (typically <10% cells engraft) (62) , and loss isolated hepatocytes into the spleen or splenic artery or directly into the portal vein. A couple of decades ago of control over the fate of the transplanted cells after their introduction into the body. Together, these issues studies demonstrated that administration of 10 4 liver cells could replace more than 80% of the liver, indicat-are likely responsible for the limited clinical success of this approach to date and the repeated finding that suc-ing that donor hepatocytes were capable of at least 12 rounds of cell division (50) . cess is greatest in small tissue volumes (e.g., rodent models).
So far, human LCT has been attempted in patients with acute liver failure (57) , in chronic liver disease with It may be possible to improve the survival and function of transplanted stem cell populations by borrowing cirrhosis (32, 58) , and in children with liver-based metabolic disease (10, 49) . To date, data concerning the effi-concepts from the tissue engineering field originally developed for the transplantation of differentiated cells (12, cacy of LCT for hepatic failure in humans has been difficult to interpret, and although clinical experiences lack 40, 46, 55, 56, 59, 64) . In particular, the tissue engineering field routinely makes use of material carriers, function-the impressive stimulant to regeneration found in animal experiments, LCT remains as an alternative experimen-ing as synthetic analogs of the extracellular matrix, to provide a substrate for transplanted cell adhesion and tal treatment to bridge patients to orthotopic transplantation or auxiliary partial orthotopic liver transplantation differentiation to control the localization of the cells in vivo, and to serve as a template for the formation of new (APOLT) with the purpose to reduce the risk related to liver transplantation in patients with clinical complica-tissue masses from the combination of transplanted cells and interfacing host cells ( Fig. 1 ). These technologies tions (49). The benefits of LCT have been extensively documented in both animal models and human trials. may prevent anoikis in the transplanted cells and also regulate their gene expression. Moreover, the material's
The laboratory data that have been accumulated suggest that hepatocytes can function in ectopic sites with some ability to induce or contain vascularization may dramatically improve cell survival and function in the host envi-clinical effectiveness (34, 45, 46, 56) . The liver, however, appears to be the most accommo-ronment. Nevertheless, although clinical success to date in tissue engineering approaches to cell transplantation dating site for engrafted hepatocytes, probably because of the availability of portal nutrients, contact with other has been limited to skin, tendons, and lately in trachea engineering (3,30), there is enough proof of principle for hepatocytes and nonparenchymal cells, proximity to paracrine factors, and the ability to secrete into the biliary the engineering of many other tissue/organ types, including the liver (12) ( Fig. 1) .
system. Hepatocytes can be seeded into the liver by intrasplenic injection, where the spleen serves as a conduit This review will provide an overview of two complementary approaches, cell transplantation and tissue engi-for the distribution of cells into the liver parenchyma or by intraportal injection (26,44,62). The migration pattern neering; both are under active investigation, to enhance the success of organ repopulation strategies and to create and cell engraftment have been evaluated by confirmation of specific molecules of the transplanted hepato-new grafts for transplantation by manipulating the biology of cells in advance of their transplantation and the cytes in the serum of animals or employing transduced cells to express the β-galactosidase gene, allowing local-development of biological scaffolds that carriers newly cells to manipulate transplanted cells in vivo and arrange ization by enzyme histochemistry, and using transgenic rodents whose hepatocytes are dipeptidylpeptidase IV the host reaction ( Fig. 1) . Cells are engineered and multiplied in culture prior to transplantation or used with minimal manipulation after harvesting or isolation and then delivered directly or utilizing bioengineering strategies. The transplanted cells are expected to home to the site of interest (e.g., liver parenchyma) or stay at the site of injection, depending on the particular application. When bioengineering delivery systems are used then cells may be allowed to adhere to a material carrier, typically a biodegradable polymer, in vitro, and subsequently be implanted or injected on the material to localize the cells to a specific anatomic site. The material serves as a guide and frame for tissue formation and typically is designed to degrade and be replaced by deposition of new extracellular matrix and cell proliferation.
(DPPIV) deficient has allowed localization using en-and tight junction between adjacent hepatocytes in the vicinity of the transplanted hepatocytes. The transplanted zyme histochemistry (20) .
Following infusion into the portal circulation, or im-cells then insert themselves between host hepatocytes, with subsequent regeneration of the bile canaliculi and plantation into the spleen, the vast majority of donor hepatocytes translocate to the liver and accumulate in gap junctions in approximately 72 h. Pharmacologic disruption of endothelial integrity and sinusoidal dilatation the hepatic sinusoids, causing transient portal hypertension that resolves in hours. Trapping of transplanted appear to improve engraftment (20) . The liver cell mass required to cure the various forms cells in hepatic sinusoids is most likely mediated by passive occlusion of the sinusoids by hepatocytes as well as of liver disease is not known yet, and animal studies are not definitive to answer this question. The number of receptor-mediated interactions between the transplanted hepatocytes and hepatic endothelial cells and compo-liver cells and transplantations required to replace function will depend on whether the indication for transplan-nents of the hepatic matrix (62) . Passage of hepatocytes into the space of Disse requires retraction of the sinusoi-tation is liver failure or metabolic deficiency. To date, LCT has not been shown to completely correct any met-dal endothelial cells. Shortly after entering the space of Disse there is a transient disruption of the gap junction abolic abnormality long term. This failure to completely correct enzyme deficiencies could be explained by the ble of contributing to the rebuilding of multiple tissues and organs (6, 36, 61) , the development of techniques to relatively small number of liver cells that engrafted in most transplant recipients due to cell quality and quan-direct the differentiation of embryonic stem cells to desirable cell populations (e.g., pancreatic beta cells) (25), tity and perhaps ineffective immunosuppression protocols. Because the number of cells that can be trans-and even recently the ability to reprogram human adult cells into pluripotent stem cells (iPS cells) (48) . The ma-planted is limited by concerns for the development of portal hypertension, repeated intraportal infusion of he-jor challenge facing this field is to transition rapidly from the identification of candidate cell populations to patocytes could be effective. Moreover, in most liverbased metabolic disorders, donor hepatocytes do not the development of effective delivery approaches ( Fig. 1) . Besides human liver cells, xenogeneic cells could be have a selective growth advantage over native hepatocytes. In laboratory animals with normal hepatic archi-a potential cell source that could address many of the challenges of treating hepatic failure. The xenotrans-tecture, hepatic irradiation and the drug retrorsine can block the proliferation of host hepatocytes, while partial plantation of hepatocytes is not limited by the availability of donors, could be performed repeatedly if needed, hepatectomy or infusion of hepatocyte growth factors, such as thyroid hormone or hepatic growth factor, could and may be effective for the treatment of viral hepatitis, because xenogeneic hepatocytes do not seem to be vul-be used to stimulate the expansion of donor hepatocytes. However, to date transplantation of a number of hepato-nerable to infection by human hepatitis viruses (63) . The most thoughtful obstacle to xenotransplantation is the cytes corresponding to 1-5% of total liver mass can be expected to have a positive impact (19, 27) .
immunological rejection of the organ graft; however, major efforts are under way to elucidate the exact mech-Cell transplantation is an elegant approach to treat or prevent liver failure that could save tens of thousands of anism involve in rejection of the cells. A recent study showed survival of porcine hepatocytes for up to 3 lives each year. However, two key obstacles prevent it reaching widespread clinical utilization: the lack of months after injection into the spleen of immunosuppressed monkeys, thus suggesting that hepatocyte xeno-transplantable cells, and poor transplanted cell engraftment leading to poor long-term functionality and viabil-transplantation from pigs could potentially become an option for patients with severe liver failure in the future ity of the transplanted cells. The evidence reviewed here strongly supports the conclusion that the realization of (35) ( Fig. 1 ). Fetal liver cell are an attractive candidate as cell cell transplantation methods would be much enhanced with the engineering of an ideal transplantable scaffold source for liver cell therapies. Fetal liver progenitor cells have shown enormous replication and differentiation po-that has all the necessary microstructure and extracellular cues for cell attachment, differentiation, functioning, tential, including the capacity to generate mature liver parenchymal and nonparenchymal liver cells after trans-and vascularization, and which can be repopulated with liver cells derived from stem cells.
plantation in normal animals. The transplanted fetal liver cells have been reported to be capable of repopulating CELL SOURCE the liver by inducing apoptosis in neighboring host hepatocytes that proliferate more slowly than the trans-Considering the limited availability of human donor livers for hepatocyte isolation, alternatives to primary planted cells in a phenomenon known as cell competition (43, 44) . The supply of fetal human tissues, however, is hepatocytes have been explored. Stem cell populations, in particular, are appealing therapeutic agents due to not unlimited and the possibility of oncogenic perturbations needs further study. It will also be important to their typically rapid and extensive proliferation and their potential to be personalized for patients. An unlimited determine whether cells derived from fetal livers before 20 weeks of gestation-when most elective abortions supply of stem cell-derived liver cells could dramatically affect the development of cell-based therapies for the are performed-would express differentiated hepatocellular function after transplantation. Further studies are treatment of liver disease and could eventually lead to therapies that could improve the lives of other patients needed to corroborate the clinical significance of this technique (Fig. 1 ). with less severe, but debilitating, liver-based metabolic disorders. The availability of reliable source of high-
The distinctive pluripotency and plasticity abilities of embryonic and induced pluripotent stem cells turn them quality liver cells would also facilitate the study of liver diseases and revolutionize the early stages of the drug into an attractive target for the development of liverbased therapies. The in vitro differentiation state of stem discovery process.
There has been tremendous progress over the past de-cells that leads to the best survival in vivo is unknown in most instances. However, it is believe that these early cade in the identification of a variety of cell populations isolated from adult and embryonic tissues that are capa-stage progenitor cells may be more efficient than fully differentiated liver cells for the growth and repopulation tionally designed from a biomaterials science perspective, where the material should provide appropriate bio-of diseased livers after transplantation because they can give rise not only to hepatocytes but also to other cell mechanical and chemical properties (3). More recently, however, the design of these materials types (nonparenchymal liver cells) including bile duct ephitelial cells required for the formation of the sophisti-has been expanded dramatically to include biological criteria that include: a) signals cells receive via adhesion cated hepatic anatomy.
Hepatic differentiation usually involves in vitro cul-to the carrier, b) soluble signals available in the cellular microenvironment, c) bioinductive properties, d) me-ture of ES cells on extracellular matrices followed by the addition of growth factors and cytokines. For this, chanical and material properties, e) host response to these biomaterials, and f) degradation properties once in several combinations of growth factors have been successfully used. Among those, activin A followed by the vivo of the materials. These various cues are intended to orchestrate the host cell response, in addition to regu-addition of FGF1 or FGF2, BMP, and HGF to induce expression of hepatic fate genes and oncostatin M lating the transplanted cell population(s). Quantitative biological design criteria will be critical for materials (OSM) and dexamethasone (Dex) for maturation, or activin A followed by sodium butyrate and HGF, have led used for stem cell culture, differentiation, and transplantation, as these cues provided by the material will likely to significant differentiation of a large number of cells with hepatic characteristics (4,6,14,55). The potential of play a crucial role in signaling cell fate and differentiation. A possible approach to generating quantitative de-those cells in the development of liver cell-based therapies has been relatively proved. sign criteria is to first develop a quantitative understanding of the relation between the cue and the target cell Care must be taken when evaluating studies describing the extent to which mature liver cells have been suc-population response.
Bioengineers are then designing a material, most of-cessfully derived from stem cells. Stem cell-derived "hepatocytes" have been generated using many strategies, ten a polymer, that provides this cue to transplanted and host cells in the desired quantity over time and space. and have been shown to secrete albumin and urea, and express cytochrome P450 (CYP) enzyme activity. How-For example, a 3D synthetic self-assembling peptide hydrogel has been used to delineate the role of concentra-ever, a more detailed analysis of gene expression, metabolic activity, growth potential, secretory function, and tions and gradients of various morphogens on angiogenesis in vitro and design material systems to promote capacity to engraft and repopulate livers will be required to determine whether such cells can fully function as angiogenesis in vivo (39,40,46,60,66).
Other approaches have involved the use of natural primary hepatocytes (4,54). extracellular matrix (ECM); the ECM is custom de-BIOENGINEERING SYSTEMS signed and manufactured by resident cells of each tissue/ FOR CELL DELIVERY organ and is in a state of dynamic equilibrium with its microenvironment (3,12). The ECM also provides a sup-Using tissue engineering techniques, researchers have studied the microstructure of the liver in order to im-portive medium or conduit for blood vessels and lymphatics and for the diffusion of nutrients from the blood prove in vitro culture techniques that allow maintenance of signals similar to the intact hepatocyte microenviron-to the surrounding cells. Thus, ECM has all the characteristics of the perfect tissue engineered scaffold/bioma-ment. These techniques have been incorporated to produce better cell delivery techniques and cell carriers.
terial for cell culture, differentiation, and transplantation.
Ideally, these bioengineered systems should provide in Extracellular Matrix as a Biologic Scaffold Material vitro conditions that reflect the in vivo environment and
for Cell Delivery they should be useful for the growth, differentiation, and "conditioning" of stem cells for subsequent in vivo Researchers have looked into the microstructure of the liver to provide inspiration for culture models that transplantation. Nutrient and oxygen transport and availability should be better regulated in these systems than maintain the signals from the hepatocyte microenvironment in vivo and provide survival and function after in monolayer cultures.
Scaling up the engineered tissue approach that could transplantation. Typical approaches involve the manipulation of the ECM environment, media composition, or be used for clinical applications will require significant improvements in the capacity to generate large-scale promotion of cell-cell interaction (3,37,39). Adhesion to a substrate is required to prevent anoikis three-dimensional (3D) tissues in vitro. Otherwise, it could be also possible to promote the growth of small and allow transplanted cell survival over even short time frames, and manipulating the presentation of adhesive engineered tissues subsequent to their introduction in vivo. Materials for cell transplantation have been tradi-cues further allows one to regulate major cellular pro-cesses over longer time. A variety of naturally derived Attempts have been made to culture cells in 3D using synthetic polymers or copolymers. These synthetic poly-ECM molecules (e.g., type I collagen and fibrin) are currently being used as cell vehicles due to their intrinsic mers are often processed into microfibers (5-20 µm).
To produce a true 3D environment, a scaffold's fibers cell binding capabilities, as are synthetic polymers to which adhesion is regulated by adsorbed proteins (52). and pores must be substantially smaller than the cells. In order to culture tissue cells in a truly 3D microenvi-Biological carries composed by natural ECM have shown to facilitate the constructive remodeling of many ronment, the fibers must be significantly smaller than cells so that the cells are surrounded by the scaffold, different tissues in both preclinical animal studies and in human clinical applications. The complex 3D organi-similar to the extracellular environment and native extracellular matrices (66) . zation of the structural and functional molecules of which the ECM is composed has not been fully charac-Animal-derived biomaterials (e.g., collagen gels, polyglycosaminoglycans, and Matrigel) have been used as terized; therefore, synthesis of this biomaterial in the laboratory is not possible. Individual components of the an alternative to synthetic scaffolds (51) . Unlike artificial matrices, animal-derived biomaterials do contain re-ECM such as collagen, laminin, fibronectin, and hyaluronic acid can be isolated and used both in vitro and in sidual growth factors, undefined constituents, or nonquantified impurities. This makes it difficult to use them vivo to facilitate cell growth and differentiation. Various forms of intact ECM have been used as biologic scaf-to grow tissues for human therapies. Animal-derived biomaterials (e.g., collagen gels, laminin, poly-glyco-folds to promote the constructive remodeling of tissues and organs (3). These ECM scaffolds have been har-saminoglycans) and materials from basement membranes including Matrigel have been used as an alterna-vested from the small intestine, skin, liver, pancreas, and urinary bladder, among other tissues. Many of these tive to synthetic scaffolds. Although researchers are well aware of their limitations, it is one of the few limited ECM materials have been even commercialized for a variety of therapeutic applications (2). A variety of these choices.
The advantages of using the designer peptide nanofi-scaffolds have been discussed and characterized elsewhere (3).
ber scaffolds are as follows: 1) One can readily modify the designer peptides at the single amino acid level at The full potential of ECM scaffolds to promote constructive remodeling is not well understood yet. The fac-will, inexpensively and quickly. 2) Unlike Matrigel, which contains unknown ingredients and quality that tors that appear important for the constructive remodeling of these natural ECM cell carriers are their ability to varies from batch to batch, artificial scaffolds may contain pure components and every ingredient is completely be rapidly and completely degraded with the generation of downstream bioactive molecules, the bioinductive defined. 3) Artificial matrices can be used to study controlled gene expression or cell signaling process. Thus, properties of the functional molecules that compose the native ECM material, and the ability to engineer its me-these scaffolds proved to be promising tools to study cell signal pathways in a selective way not possible with chanical properties at the time of implantation. However, its sophisticated and complicated microstructure any unknown substrates that could result in confusing cell signaling activation. 4) These scaffolds could pro-needs to be further characterized. In addition, the effect of various processing steps to produce the biological vide the opportunity to incorporate a number of different functional motifs and their combinations to study cell ECM may impact the host immune response.
behavior in a well-defined ECM-analog microenviron-Artificial Matrix for Cell Delivery ment, not only without any chemical cross-link reactions but also fully bioreabsorbable scaffolds. Synthetic peptides mediating adhesion can also be presented to cells as self-assembling hydrogels, coupled
In addition, a new technology that involves the creation of an artificial liver tissue by layering thermore-as side chains to polymer backbones, or as components of synthetic proteins that provide desirable combinations sponsive cultured cell sheets in vitro and then transplanting them directly into the subcutaneous space has been of cell interactive domains and overall physical/chemical properties.
recently introduced, which was demonstrated to stably persist for over 200 days (46) . We still do not know, In the past three decades, several biopolymers, including PLLA, PLGA, PLLA-PLGA copolymers, and however, if graft survival lasting months in rodents will translate into a more prolonged survival in patients, or other biomaterials, including alginate, agarose, and collagen gels, have been developed to culture cells in 3D whether a sufficient functional cell mass can be transplanted. (8, 21, 28) . These culture systems have significantly advanced our understanding of cell-material interactions Even with all the advances produced in the last years, there has not yet been a definitive demonstration that the and cell delivery and facilitated the perception of a new field of tissue engineering and regenerative medicine. mechanical properties of the adhesion substrate regulate tissue formation by transplanted cells in vivo. This likely livery and waste removal in the tissue engineered construct. relates to the difficulty in separating mechanical and degradative properties of materials, and the material degra-CELL TRANSPLANTATION dation rate clearly plays an important role in the ability TO ENGINEER ORGANS of transplanted cells to deposit new matrix and remodel the tissue.
A significant challenge to the successful implementation of cell therapies to engineered organs is the integra-Whole Organ Scaffolds for Tissue Engineering tion of the new cells within the vascular, lymphatic, and nervous systems of the host matrix or decellularized or-The first-generation tissue engineering materials have found limited use as they had limited ability to modulate gan. Engineering of sophisticated cell organizations (e.g., liver) is especially challenging. The liver is com-the repair and regeneration of the host tissue. Consequently, material and host tissue interactions became an posed of several distinct cell types, including hepatocytes, sinusoid endothelial, Kupffer, stellate, and biliary important consideration in the design of new materials such that the new generation materials should harness epithelial cells (Fig. 2) . These cells are orchestrated through tight junctions and connective tissue such as elements that regulate tissue regeneration by different mechanisms, such as controlling specific cell binding in-type I and IV collagen and laminins. The need for vascularization is motivated by the ob-teractions and responding to environmental cues (29) . In addition, because material microstructure has been servation that transplanted cells will rapidly die if they are placed a significant distance from the host vascula-found to play an important role for tissue morphogenesis (11, 23) , 3D aspects such as pore structure, surface area ture (53) . Researchers have attempted various approaches via angiogenesis, by 1) providing local and sustained to volume ratio, texture, and surface topography that define material architecture have become other important presentation of angiogenic molecules (this technique has been demonstrated to enhance vascularization and perfu-design parameters (5). Considering these design constraints, decellularized ECM represents an ideal material sion in vitro and in the implant site) (55), and 2) other strategies have included the co-seeding of endothelial for tissue engineering applications as it retains relevant aspects of complex structure and chemical composition cells and supportive fibroblast that spontaneously form capillary-like networks, and the engineering of branching of the ECM (12) . Moreover, using perfusion decellularization technique described recently for heart (47) , the channels to mimic the vascular tree (38) . However, these efforts have not yet produced a scaffold that has a natu-native 3D structure of the organ can also be preserved, which will most likely provide the necessary architec-ral vascular tree with centralized inlet and outlet vessels and a pervasive nutrient exchange capacity comparable ture for optimal cell distribution and subsequent tissue morphogenesis. The intent of most decellularization pro-to the capillary network in the body. Thus, a significant advance in the field of organ engineering has been the cesses is to minimize the disruption and thus retain native mechanical properties and biologic properties. The utilization of decellularized tissue/organs as skeleton for cell implantation in a 3D environment (3,47). most commonly utilized methods for decellularization of tissues involve a combination of physical and chemical Recently, a work was published reporting that a whole-heart scaffold with intact 3D geometry and vascu-treatments. The physical treatments can include agitation or sonication, mechanical massage or pressure, or freez-lature was attempted by decellularization of cadaveric hearts by coronary perfusion with detergents. This work ing and thawing. These methods disrupt the cell membrane, release cell contents, and facilitate subsequent demonstrated that the natural scaffold could be then repopulated with neonatal cardiac cells or rat aortic endo-rinsing and removal of the cell contents from the ECM. These physical treatments are generally insufficient to thelial cells and cultured these recellularized constructs under simulated physiological conditions for organ mat-achieve complete decellularization and must be combined with a chemical treatment. Enzymatic treatments, uration. Cellularization of these decellularized hearts was performed by infusion of cells through direct perfu-such as trypsin, and chemical treatment, such as ionic solutions and detergents, disrupt cell membranes and the sion of the coronary vasculature or direct puncture into the decellularized scaffold. Even though the actual con-bonds responsible for intercellular and extracellular connections. Tissues are composed of both cellular material tractile function was almost 2% compared to normal contractile function, this work represents an example of and ECM arranged in variable degrees of compactness depending on the source of the tissue. organ engineering using decellularized natural scaffolds (47) . Most interestingly, a report showed the first human In addition, the scaffold obtained via perfusion-decellularization will contain a perfusable vascular tree that clinical tracheal transplantation using a cadaveric trachea with cartilage structure as matrix. This tissue engi-facilitates in vitro perfusion and reconnection to the blood torrent, and this can greatly enhance nutrient de-neered graft was successfully implanted in the left main bronchus of a 30-year-old woman. The trachea was de-and accumulates in the hepatic sinusoids, causing important portal hypertension. Trapping of transplanted cells cellularized over a period of 6 weeks and seeded with a combination of epithelial cells and bone marrow stromal in hepatic sinusoids is most likely mediated by passive occlusion of the sinusoids by hepatocytes as well as re-cells from the own patient for a period of time of 96 h. This important and innovative report demonstrates the ceptor-mediated interactions between the transplanted hepatocytes and hepatic endothelial cells and compo-principle that a cellular therapy combined with tissue engineering can produce engineered organs with impor-nents of the hepatic matrix. Only a small fraction of hepatocytes ultimately engraft in the liver after intraportal tant implications for serious clinical disorders (30) .
However, cell seeding of these multidimensional arti-injection (5-20%) (Fig. 2) . Thus, intrasplenic transplantation has been the preferred site for transplantation, ficial and naturally derived scaffolds presents challenges for whole organ engineering, particularly the human where the spleen serves as a conduit for the distribution of cells over time. On the other hand, pharmacologic liver, which contains a dense cell mass (estimated as 10 × 10 10 cells). Naturally, the intact liver vascular tree disruption of endothelial integrity and sinusoidal dilatation appear to improve engraftment. Even so, a major is accessible through one central inlet (portal vein), which branches into a capillary-like network and then limiting factor to intraportal engraftment is the number of viable cells that can be safely injected at one time reunites into one central outlet. Classically, liver cells are transplanted via portal vein or intrasplenic. Follow- (9, 10, 57) . Based on this funded knowledge of liver cell trans-ing rapid infusion into the portal circulation, the vast majority of donor hepatocytes translocates to the liver plantation, theoretically, cellularization of naturally de-cellularized liver scaffold might be done over extended likely prevent full function and probably lead to atrophy in many situations. The recent recognition of significant period of times, using limited cell numbers at each time. Even if these scaffolds lack of cellular components, they molecular crosstalk between the nervous and vascular systems during development (65) and regenerative pro-still have vasculature network that is well conserved. Thus, one can hypothesize that there might be a barrier cesses may provide multiple targets to simultaneously enhance innervations and vascularization of engineered that hepatocytes might have to cross to fully integrate in the liver parenchyma. Additionally, it might be neces-organs. sary to provide cells through retrograde flow from the FUTURE PERSPECTIVES AND CONCLUSIONS vena cava that would enter the liver lobule through the central vein and deposit cells in the pericentral area. In Cell transplantation is an elegant approach to treat or this way, we could have cells seeded in the periportal prevent liver failure that could save tens of thousands of and pericentral area.
lives each year. However, two key obstacles prevent it Alternatively, endothelial cells or progenitors may be reaching widespread clinical utilization: the shortage of added in concert with the cell type of interest and it transplantable cells, and poor engraftment leading to may also contribute to the formation of a new vascular poor long-term functionality and viability of the transnetwork that enhances cell survival and tissue formation.
planted cells. The evidence reviewed here strongly sup-Endothelial coverage of the decellularized vascular ports the conclusion that the realization of cell transplanstructures lumen of the bioscaffold would be essential tation methods would be much enhanced with the to prevent thrombosis and to provide proper vascular engineering of an ideal transplantable scaffold that has function. Thus, the addition of nonparenchymal cells all the necessary microstructure and extracellular cues would be ideal to reconstitute the liver sinusoid (Fig. 2) .
for cell attachment, differentiation, functioning, and vas-Perhaps the addition of supportive cells (e.g., fibroblast cularization, and which can be repopulated with liver or mesenchymal stromal cells) would enhance the secrecells derived from stem cells. An exciting possibility is tion of native matrices for adequate cell repopulation utilizing decellularized liver extracellular matrix as the and reorganization. Yet the problem of the engineering scaffold for cell transplantation, which could ultimately of the biliary tract and reconnection to the existing biliallow the development of an engineered auxiliary liver ary conducts should be address. But the use of stem cells grafts for transplantation and open the doors to a new and bipotent cells (e.g., fetal liver cells) might represent era of organ engineering. a source for this issue. lowing temporal and spatial control over differentiation.
